Bevacizumab continuation versus treatment holidays after first-line chemotherapy with bevacizumab in patients with metastatic colorectal cancer: a health economic analysis of a randomised phase III trial (SAKK 41/06)
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Matter-Walstra K, Schwenkglenks M, Dedes KJ.
Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available.
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.
Breast Cancer Res Treat. 2016 Jul;158(1):51-7. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.